PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 64380

Cellular subclasses in human leukemic hemopoiesis.

J E Till·T W Mak·G B Price·J S Senn·E A McCulloch
View original source ↗Export metadata ↓

Abstract

Cellular organization and communication in leukemic hemopoiesis may be compared with its counterpart in normal hemopoiesis. Results obtained using cell culture methods have provided some support for the view that leukemic hemopoiesis, like normla hemopoiesis, may involve 3 levels of differentiation: leukemic stem cells, committed leukemic progenitors, and more mature cells. Evidence is also beginning to emerge that leukemic populations may be regulated by messages from the environment in a manner analogous to normal hemopoiesis. The apparent similarities between leukemic and normal hemopoiesis raise, the possibility that the target cell for leukemic transformation is the normal pluripotent stem cell. The development of culture methods for the production of leukovirus-like particles from human leukemic cells provides a possible first step toward the direct identification of leukemic target cells.

Explore related subjects

Anemia, SideroblasticCell DifferentiationCell DivisionCells, CulturedColony-Stimulating FactorsGranulocytesHematopoiesisHematopoietic Stem CellsLeukemiaLeukocytesRNA-Directed DNA PolymeraseJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J E Till, T W Mak, G B Price, J S Senn, E A McCulloch. 1976. Cellular subclasses in human leukemic hemopoiesis.. https://doi.org/10.1007/978-3-642-87524-3_4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Sideroblastic anemias].

Sideroblastic anemias are a heterogenous group of disorders characterized by the presence of sideroblasts in the bone marrow aspirate. Current classification schemes distinguish between diseases of the heme synthesis pathway and diseases of other mitochondrial pathways which can either be of primary origin (defects in mitochondrial DNA) or of secondary origin (defects in nuclear DNA). Although several distinct hereditary forms exist, sideroblastic anemias are most frequently acquired diseases and belong to the group of myelodysplastic syndromes with the propensity to develop into overt leukemia. Treatment is mainly supportive (vitamins, blood transfusions, cytokines) and only rarely are bone marrow transplantations performed. The molecular defects of a few hereditary forms have already been elucidated, but the genes involved in the acquired forms are still largely unknown.

Anemia, Sideroblastic↗
PubMed2006

Congenital sideroblastic anemias.

Congenital forms of sideroblastic anemia constitute a subset of uncommon disorders within the wider spectrum of sideroblastic anemias, all of which are diagnosed by the presence of pathologic iron deposits in erythroblast mitochondria. The congenital sideroblastic anemias are heterogeneous disorders; some arise from known molecular defects but others are diagnosed only by their clinical features. Elucidation of several of the underlying defects has advanced our understanding of heme biosynthesis and iron metabolism in the erythroid cell. With the details of the porphyrin synthetic pathway clarified, now the important frontier of research is investigation of the mechanisms of mitochondrial and cellular iron homeostasis and their relationship to the regulation of heme biosynthesis. Knowledge gained from efforts in this area of study may also provide new approaches to treatments, which remain largely supportive for most types of congenital sideroblastic anemia.

Anemia, Sideroblastic↗
PubMed2005

Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation.

A missense mutation in the PUS1 gene affecting a highly conserved amino acid has been associated with mitochondrial myopathy and sideroblastic anemia (MLASA), a rare autosomal recessive oxidative phosphorylation disorder. The PUS1 gene encodes the enzyme pseudouridine synthase 1 (Pus1p) that is known to pseudouridylate tRNAs in other species. Total RNA was isolated from lymphoblastoid cell lines established from patients, parents, unaffected siblings, and unrelated controls, and the tRNAs were assayed for the presence of pseudouridine (Psi) at the expected positions. Mitochondrial and cytoplasmic tRNAs from MLASA patients are lacking modification at sites normally modified by Pus1p, whereas tRNAs from controls, unaffected siblings, or parents all have Psi at these positions. In addition, there was no Pus1p activity in an extract made from a cell line derived from a patient with MLASA. Immunohistochemical staining of Pus1p in cell lines showed nuclear, cytoplasmic, and mitochondrial distribution of the protein, and there is no difference in staining between patients and unaffected family members. MLASA is thus associated with absent or greatly reduced tRNA pseudouridylation at specific sites, implicating this pathway in its molecular pathogenesis.

Anemia, Sideroblastic↗